VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on September 11, 2026. The report details a specific corporate event regarding the prepayment of a senior secured convertible promissory note.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial event reported is as follows:
- Note Prepayment: The Company prepaid approximately $422,000 in cash on September 11, 2026.
- Instrument: This payment settled the outstanding principal of the "2025 Note" (originally $7,500,000 principal amount issued May 20, 2025).
- Outstanding Debt: The "2026 Note" (original principal $2,400,000) remains in full force and effect.
Material Changes
The primary material change is the reduction of debt obligations. Following the prepayment, no further amounts remain outstanding under the 2025 Note. The filing explicitly states that the 2026 Note and associated obligations were not affected by this transaction.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the debt transaction. A press release dated September 14, 2026, regarding the prepayment is included as an exhibit.
Investor Verification Checklist
- Verify the remaining balance and terms of the outstanding 2026 Note with Lind Global Asset Management XII LLC.
- Confirm the cash impact of the $422,000 prepayment on the Company's current liquidity position.
- Review the attached press release (Exhibit 99.1) for additional context on the prepayment rationale.
- Check subsequent filings for any updates on the 2026 Note or new financing activities.